The number of COVID-19 indicated medical devices gaining approval in Q3 2021 saw a flat growth when compared with Q2 2021, according to GlobalData’s medical devices marketed products database
Compared with Q3 2020, the number of COVID-19 indicated medical devices gaining approval in Q3 2021 saw a 58% drop globally.
Europe tops COVID-19 approved medical devices activity
Comparing COVID-19 medical device approvals activity in different regions of the globe, Europe held the top position for approved products (55%) in Q3 2021, followed by North America (24%), and Asia-Pacific (20%).
On a country level, the Germany had the most COVID-19 approved medical devices during the quarter, representing the largest share (50%) of the global market. In second place was United States with a share of 20%, followed by Australia with 8%.
Go deeper with GlobalData
COVID-19 marketed medical devices: Development activity in Q3 2021
GlobalData’s database indicated that CE-IVD marketed medical devices that addressed the COVID-19 pandemic accounted for 32% of medical devices in Q3 2021, compared with 32% in Q2 2021.
COVID-19 medical devices obtaining EUA approval declined to 42% in Q3 2021, compared with Q2 2021.
EUA have become more common during the COVID-19 pandemic, as an expeditious mechanism to bring therapeutic devices to market more quickly than normal device approvals.
Company-developed COVID-19 medical devices lead in Q3 2021
GlobalData’s databases indicated that company-developed medical devices accounted for a 97% share of approved COVID-19 devices globally during Q3 2021, while institute-developed marketed products held the remaining share.
The quarterly average for Q3 2021 saw 97% of approved COVID-19 indicated devices originating from private and public companies, and 3% from institutes.
Methodology
The Covid-19 medical devices approval data used in this article were extracted from Medical Marketed Products Database of GlobalData’s Medical Intelligence Center. Marketed Products database covers all commercialized medical devices which are intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Marketed products are covered from regulatory bodies like US FDA, company websites, news releases, SEC filings etc. The information is collected by following systematic research techniques and proprietary methodology.
